Dermatologists explain the science behind wildly popular treatments like red light therapy, which is now available at home—for a steep price. Full-face LED masks like this one can cost up to several ...

Interstitial cystitis is a chronic bladder condition that can cause pelvic pressure and pain. Lifestyle changes, medication, and surgery can treat IC.

Wanza, who runs a family-owned seafood business named Gropper Seafood, was 40 years old when her four-year-old daughter, who ...

… a video purporting to be a segment on Fox News (it wasn’t) in which an A.I.-generated, deep-faked version of himself sat in the White House and promised that “every American will soon receive their ...

CHICAGO (WLS) -- Dozens of qualified swimmers jumped into the Chicago River on Sunday morning. The Chicago River Swim marked the return of competitive open-water swimming in the river in nearly a ...

Why are we asking for donations? Why are we asking for donations? This site is free thanks to our community of supporters. Voluntary donations from readers like you keep our news accessible for ...

Hi, I’m Luke! I’m passionate about buying, selling, breeding, and keeping goldfish — and I’ve built a space to share everything I’ve learned along the way. Whether you’re new to goldfish keeping or a ...

CHICAGO – Every year, the plumbers' union dyes it green. The Dave Matthews Band once infamously dumped 800 pounds of poop into it. And at least one section became known for the bubbles produced by ...

Inlexzo is a new treatment for a type of bladder cancer in adults that hasn’t spread to the muscles and doesn’t respond to Bacillus Calmette-Guérin (BCG) therapy. It’s approved for treating non-muscle ...

The FDA has approved a gemcitabine intravesical system for Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), either with or without ...

Inlexzo is approved for BCG-unresponsive NMIBC with CIS, offering a new treatment option for patients with limited alternatives. The SunRISe-1 trial showed an 82% complete response rate, with 51% ...